Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Regado Biosciences
Evaluate
March 10, 2015
NASH craze lives on, despite the unknowns
December 24, 2014
Cyclacel and Neovacs enter the graveyard shift
August 26, 2014
Regado pays steep price to avert full phase III cost
July 03, 2014
Forget the binary outcome; Regado faces a bigger problem
April 14, 2014
Lombard postpones IPO as US indices decline
January 06, 2014
Fast times in biotech push IPO count to new highs
September 17, 2013
Regado remains a huge binary bet despite share price bump
February 05, 2010
EP Vantage Interview - Regado seeking solution to clotting conundrum
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 15, 2023
Pharma’s Biggest Spenders 2022 Infographic
May 03, 2023
Gene Editing: Overhyped or Unstoppable Tide?
Editor's Picks
May 16, 2023
Heightened US antitrust fears rattle biopharma
May 11, 2023
2023’s biggest launches: the story so far
May 17, 2023
Viking’s Voyage is not over yet
May 09, 2023
Gene editing: overhyped or unstoppable tide?
May 16, 2023
A slow (and low) year for FDA approvals